AVRX Avalon Pharmaceuticals (MM)

GERMANTOWN, Md., May 8 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX), today announced that Kenneth C. Carter, Ph.D., President and CEO, is scheduled to provide an update on the Company at the Rodman & Renshaw 4th Annual Global Healthcare Conference. The conference will be held on May 14-15, 2007 and Dr. Carter is scheduled to present on Monday, May 14, at 3:15 p.m. CEST (Central European Summer Time), 9:15 a.m. EDT (Eastern Daylight Time). The presentation will be available live via a webcast and can be accessed through the investor page of Avalon Pharmaceuticals' website at: http://www.avalonrx.com/. An archive of the presentation will be available for 30 days following the conference. About Avalon Pharmaceuticals Avalon Pharmaceuticals is a biopharmaceutical company using its proprietary technology, AvalonRx(R), to discover and develop cancer therapeutics. Avalon has a lead product in Phase I clinical development (AVN944 -- IMPDH inhibitor), as well as preclinical programs to discover inhibitors for the beta-catenin and aurora pathways now in late stage lead candidate optimization. Avalon also has discovery programs on modulators of survivin function and a drug discovery program targeting the MYC oncoprotein, one of the most important and previously intractable cancer targets. The company has value generating partnerships with Merck, MedImmune, Medarex, and Novartis. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Md. Contacts: Avalon Pharmaceuticals, Inc. Russo Partners, LLC David D. Muth Wendy Lau (Media) Executive Vice President & Tel: (212) 845-4272 Chief Business Officer Tel: (301) 556-9900 The Trout Group LLC Fax: (301) 556-9910 Chad Rubin (Investors) Email: Tel: (646) 378-2947 DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: David D. Muth, Avalon Pharmaceuticals, Inc. Executive Vice President & Chief Business Officer, +1-301-556-9900, fax, +1-301-556-9910, or ; or Media, Wendy Lau of Russo Partners, LLC, +1-212-845- 4272, or Investors, Chad Rubin of The Trout Group LLC, +1-646-378-2947, both for Avalon Pharmaceuticals, Inc. Web site: http://www.avalonrx.com/

Copyright